Event-Driven Stocks

ASSEMBLY BIOSCIENCES, INC.

ASMBNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 4 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$72.3M$28.5M$7.2M$0$6.3M$79.1M
Operating income−$12.1M−$45.4M−$64.6M−$94.1M−$132.7M−$64.8M
Net income−$6.1M−$40.2M−$61.2M−$93.1M−$129.9M−$62.2M
Total assets$257.6M$119.2M$136.8M$101.8M$191.1M$283.3M
Total liabilities$50.8M$85.8M$95.7M$19.1M$22.1M$42.7M
Equity$206.8M$33.4M$41.1M$82.7M$168.9M$240.6M
EPS (diluted)$-0.55$-6.69$-13.38$-23.08$-3.00$-0.76
Shares out.7.5M5.5M51.9M48.1M38.2M32.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−16.8%
Net margin
−8.5%
Return on equity
−3.0%
Return on assets
−2.4%
Return on capital (ROCE)
−5.8%
Liabilities / assets
19.7%
Debt / equity
0.25×
Book value / share
$27.55
Revenue growth (YoY)
153.5%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-1.34distress
Accruals / assets
13.6%high accruals
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
55
/ 100
Profitability 0Growth 100Catalyst 100Earnings quality 0Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
8 acquisitions0 disposals1 open-market buy(s)net +2.9M shares · last 8
InsiderDateTypeSharesPrice
Gilead Sciences, Inc.10% ownerMay 26, 2026Grant471,698$26.50
Bjorkquist Jeanette MOfficer — PFO and PAOMar 29, 2026Grant6,500$0.00
White Nicole SOfficer — Chief Manufacturing OfficerMar 29, 2026Grant26,000$0.00
Gaggar AnujOfficer — Chief Medical OfficerMar 29, 2026Grant26,000$0.00
Delaney William E IvOfficer — Chief Scientific OfficerMar 29, 2026Grant26,000$0.00
Okazaki Jason AOfficer — CEO and PresidentMar 29, 2026Grant94,250$0.00
Gilead Sciences, Inc.10% ownerAug 8, 2025Buy2.3M—
Bjorkquist Jeanette MOfficer — PFO and PAOJun 16, 2025Grant300$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.5M9.4-0.9%
Apr 30, 20261.6M15.5+1.7%
Apr 15, 20261.5M16.4-0.1%
Mar 31, 20261.5M22.4+0.8%
Mar 13, 20261.5M18.5+2.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)